Background: Sebaceous carcinoma may masquerade for years as an inflammatory condition. In many cases, this may be because of the presence of longstanding intraepithelial disease (e.g., dysplasia or carcinoma in situ), which eventually progresses to invasive carcinoma recognized through tumefaction and a worsening clinical presentation. The mechanism for this tumor progression is unknown. In the Far East, human papilloma virus (HPV) has been suggested to play a role in the development of sebaceous carcinoma by inactivating tumor suppressor gene p53. Here, the authors explore the molecular basis of the progression of ocular sebaceous carcinoma.
Methods: Cases of sebaceous carcinoma seen at the University of Virginia, Department of Ophthalmology, during the period from 1989 to 1996 were analyzed for HPV infection by in situ hybridization and polymerase chain reaction. The expression of p53, p21WAF-1, Bcl-2, and epithelial membrane antigen was examined by immunohistochemistry. In one of the cases, frozen tumor was available, allowing exons 5 through 9 of the p53 gene to be sequenced.
Results: Seven cases were identified, all of which were from women. All were negative for HPV. In cases in which disease was restricted to dysplasia (carcinoma in situ), p53 but not p21WAF-1 was negative. In contrast, cases that contained a component of invasive or metastatic carcinoma showed striking hyperexpression of nuclear p53 in all of the malignant cells. In one of these cases, a G:C-->T:A transversion was found in the p53 gene. This mutation, characteristic of bulky carcinogens, substituted phenylalanine for cysteine 277, a residue that participates in hydrogen bonding to the p53 DNA binding consensus sequence.
Conclusions: Mutational inactivation of p53 may be involved in the progression of sebaceous carcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S0161-6420(98)93034-2 | DOI Listing |
Clin Exp Dermatol
January 2025
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Background: One in five sebaceous tumour (ST) patients may have Lynch syndrome (LS), a hereditary cancer predisposition. LS patients benefit from cancer surveillance and prevention programmes and immunotherapy. Whilst universal tumour mismatch repair (MMR) deficiency testing is recommended in colorectal and endometrial cancers to screen for LS, there is no consensus screening strategy for ST, leading to low testing rates and inequity of care.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Dermatovenereology, Chengdu Second People's Hospital, Chengdu, Sichuan, China.
Nevus sebaceous (NS) is a congenital hamartoma characterized by the presence of skin structures, including the epidermis, sebaceous glands, and hair follicles. NS predominantly occurs on the scalp and has the potential to give rise to secondary tumors, with a small proportion being malignant; the most frequently observed malignant tumor associated with NS is basal cell carcinoma. In this report, we retrospectively present four cases of sebaceous nevus on the scalp complicated by basal cell carcinoma.
View Article and Find Full Text PDFAn Bras Dermatol
January 2025
Department of Dermatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. Electronic address:
Arch Dermatol Res
January 2025
Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, 40126, Italy.
Invest Ophthalmol Vis Sci
January 2025
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Purpose: To evaluate the prognosis of eyelid sebaceous carcinoma (SeC) in patients with disease stage worse than IIA.
Methods: This retrospective, single-center study included 78 SeC patients. For stage II patients, 1:3 propensity score matching (PSM) was applied between those undergoing orbital exenteration and those receiving eye-sparing treatments.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!